GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (OTCPK:MEOBF) » Definitions » Cyclically Adjusted Price-to-FCF

Mesoblast (Mesoblast) Cyclically Adjusted Price-to-FCF : (As of Apr. 29, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Mesoblast Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Mesoblast Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Mesoblast's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Cyclically Adjusted Price-to-FCF Chart

Mesoblast Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Mesoblast Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mesoblast's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Mesoblast's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mesoblast's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mesoblast's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Mesoblast's Cyclically Adjusted Price-to-FCF falls into.



Mesoblast Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Mesoblast's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Mesoblast's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0/125.6559*125.6559
=0.000

Current CPI (Dec. 2023) = 125.6559.

Mesoblast Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201306 0.000 95.473 0.000
201312 0.000 97.330 0.000
201406 0.000 98.352 0.000
201412 0.000 99.002 0.000
201503 0.000 99.187 0.000
201506 0.000 99.838 0.000
201509 -0.081 100.302 -0.101
201512 -0.053 100.673 -0.066
201603 -0.055 100.488 -0.069
201606 -0.045 100.859 -0.056
201609 -0.053 101.602 -0.066
201612 -0.063 102.159 -0.077
201703 -0.061 102.624 -0.075
201706 -0.052 102.809 -0.064
201709 -0.044 103.460 -0.053
201712 -0.030 104.110 -0.036
201803 -0.039 104.574 -0.047
201806 -0.040 104.945 -0.048
201809 -0.039 105.410 -0.046
201812 0.004 105.967 0.005
201903 -0.040 105.967 -0.047
201906 -0.036 106.617 -0.042
201909 -0.030 107.174 -0.035
201912 -0.003 107.917 -0.003
202003 -0.036 108.289 -0.042
202006 -0.025 106.246 -0.030
202009 -0.046 107.917 -0.054
202012 -0.001 108.846 -0.001
202103 -0.040 109.496 -0.046
202106 -0.028 110.332 -0.032
202109 -0.027 111.168 -0.031
202112 -0.027 112.654 -0.030
202203 -0.023 115.069 -0.025
202206 -0.020 117.112 -0.021
202209 -0.020 119.248 -0.021
202212 -0.021 121.477 -0.022
202303 -0.021 123.148 -0.021
202306 -0.020 124.170 -0.020
202309 -0.017 125.656 -0.017
202312 0.000 125.656 0.000

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Mesoblast  (OTCPK:MEOBF) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Mesoblast Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Mesoblast's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Mesoblast (Mesoblast) Business Description

Industry
Traded in Other Exchanges
Address
Level 38, 55 Collins Street, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.